OTCMKTS:ARTH - Arch Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.40 0.00 (0.00 %) (As of 09/21/2018 04:00 PM ET)Previous Close$0.40Today's Range$0.3904 - $0.4252-Week Range$0.25 - $0.84Volume122,290 shsAverage Volume293,730 shsMarket Capitalization$63.93 millionP/E RatioN/ADividend YieldN/ABeta0.7 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts. Receive ARTH News and Ratings via Email Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical SymbolOTCMKTS:ARTH CUSIPN/A Webwww.archtherapeutics.com Phone617-431-2313 Debt Debt-to-Equity RatioN/A Current Ratio18.77 Quick Ratio18.77 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.01 per share Price / Book40.00 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,780,000.00 Net MarginsN/A Return on Equity-254.30% Return on Assets-115.86% Miscellaneous Employees10 Outstanding Shares159,820,000Market Cap$63.93 million Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions What is Arch Therapeutics' stock symbol? Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH." How were Arch Therapeutics' earnings last quarter? Arch Therapeutics Inc (OTCMKTS:ARTH) posted its quarterly earnings data on Tuesday, May, 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). View Arch Therapeutics' Earnings History. When is Arch Therapeutics' next earnings date? Arch Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, September, 27th 2018. View Earnings Estimates for Arch Therapeutics. What price target have analysts set for ARTH? 4 equities research analysts have issued 12-month price targets for Arch Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Arch Therapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 650.0% from the stock's current price. View Analyst Price Targets for Arch Therapeutics. What is the consensus analysts' recommendation for Arch Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics. Who are some of Arch Therapeutics' key competitors? Some companies that are related to Arch Therapeutics include Pulse Biosciences (PLSE), SeaSpine (SPNE), Invuity (IVTY), Apollo Endosurgery (APEN), Endologix (ELGX), Alphatec (ATEC), RenovaCare (RCAR), Sensus Healthcare (SRTS), STRATA Skin Sciences (SSKN), Motus GI (MOTS), Restoration Robotics (HAIR), Repro-Med Systems (REPR), Invo Bioscience (IVOB), CAS Medical Systems (CASM) and Neovasc (NVCN). Who are Arch Therapeutics' key executives? Arch Therapeutics' management team includes the folowing people: Dr. Terrence W. Norchi, Co-Founder, Pres, CEO, Sec. & Director (Age 53)Mr. Richard E. Davis, Chief Financial Officer and Treasurer (Age 60)Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific AdvisorDr. Steven A. Kates Ph.D., VP of Technology Has Arch Therapeutics been receiving favorable news coverage? Media coverage about ARTH stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arch Therapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. View Recent Headlines for Arch Therapeutics. How do I buy shares of Arch Therapeutics? Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Arch Therapeutics' stock price today? One share of ARTH stock can currently be purchased for approximately $0.40. How big of a company is Arch Therapeutics? Arch Therapeutics has a market capitalization of $63.93 million. Arch Therapeutics employs 10 workers across the globe. How can I contact Arch Therapeutics? Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected] MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 128 (Vote Outperform)Underperform Votes: 122 (Vote Underperform)Total Votes: 250MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/21/2018 by MarketBeat.com StaffFeatured Article: What are the reasons investors use put options?